H.C. Wainwright has recently reduced Fulcrum Therapeutics Inc (FULC) stock to Neutral rating, as announced on September 13, 2024, according to Finviz. Earlier, on September 12, 2024, Stifel had reduced the stock from a Buy to Hold. RBC Capital Mkts also reduced Sector Perform rating with a price target of $4. Additionally, Leerink Partners reduced Market Perform rating on September 12, 2024, with a target price of $4. Cantor Fitzgerald analysts, in their report published on September 12, 2024, also reduced Neutral rating for Fulcrum Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Fulcrum Therapeutics Inc (FULC) Stock Trading Recap
On Monday, Fulcrum Therapeutics Inc (FULC) stock saw a decline, ending the day at $3.57 which represents a decrease of $-0.20 or -5.31% from the prior close of $3.77. The stock opened at $3.75 and touched a low of $3.57 during the day, reaching a high of $3.83. The volume of shares traded was 0.88 million falling short of the average volume of 1.83 million.
FULC Stock Performance and Moving Averages
In recent trading, Fulcrum Therapeutics Inc (FULC) stock price has shown some volatility, fluctuating 11.56% over the last five trades and -59.15% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -61.65%, and it has plunged by -43.42% in the previous three months. Currently, FULC is trading at -34.60%, -52.70%, and -54.48% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, FULC, a Healthcare sector stock, is trading -73.94% below its 52-week high but remains 24.61% above its 52-week low. The Average True Range (ATR) (14 days) of 0.66 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Fulcrum Therapeutics Inc’s Profitability and Valuation Ratios
Fulcrum Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -40.15% and a profit margin of -24.79%, with a gross margin of -61.65%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Fulcrum Therapeutics Inc’s market capitalization stands at $222.77 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 2.73, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 0.81, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 15.49% of Fulcrum Therapeutics Inc (FULC)’s shares, while financial institutions hold 82.05%.
